版本:
中国

BRIEF-Alkermes announces initiation of study 217 for ALKS 5461

June 12 Alkermes Plc

* Alkermes announces initiation of study 217 for ALKS 5461 for treatment of major depressive disorder

* ‍phase 3B study designed to further evaluate ALKS 5461's potential benefits on mood domains regulated by endogenous opioid modulation​

* ‍Company reiterates plans to submit new drug application to FDA by year-end 2017​ Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐